| Literature DB >> 487815 |
A Barfield, J Melo, E Coutinho, F Alvarez-Sanchez, A Faundes, V Brache, P Leon, J Frick, G Bartsch, W H Weiske, P Brenner, D Mishell, G Bernstein, A Ortiz.
Abstract
A potential male contraceptive approach was evaluated in clinical trials involving monthly injections of depot medroxyprogesterone acetate and either subdermal implants of testosterone propionate or monthly injections of testosterone enanthate. Pregnancies occurred in partners of 9 men with recent sperm counts of 10 million/ml or below. In 5 of the 9 instances, the sperm counts were less than 1 million/ml. It appears that male contraceptive methods involving spermatogenic suppression may require attainment and maintenance of azoospermia. The pregnancy rate cannot be calculated, because the extent of other contraceptive use is uncertain. There were no spontaneous abortions. 6 pregnancies were carried to term, and all progeny were normal, based on physical examination at birth or 3 months after birth.Entities:
Keywords: Androgens; Biology; Clinical Research; Contraception; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents--administraction and dosage; Economic Factors; Endocrine System; Examinations And Diagnoses; Family Planning; Genitalia; Genitalia, Male; Hormones; Infertility; Laboratory Examinations And Diagnoses; Laboratory Procedures; Medroxyprogesterone Acetate--administraction and dosage; Men; Physiology; Pregnancy; Reproduction; Research And Development; Research Methodology; Semen--analysis; Seminal Vesicles; Sperm Count; Technology; Testosterone--administraction and dosage; Urogenital System
Mesh：
Substances：
Year: 1979 PMID： 487815 DOI： 10.1016/0010-7824(79)90084-2
Source DB: PubMed Journal: Contraception ISSN： 0010-7824 Impact factor: 3.375